Eko Analysis Software vs ElucidVivo A.3
AI Verdict
Choose Eko Analysis Software if…
Choose Eko Analysis Software if your primary need is real-time, AI-assisted auscultation and early detection of common cardiovascular conditions like heart murmurs and atrial fibrillation during routine physical exams or telehealth consultations. This tool is ideal for clinicians seeking to enhance their diagnostic capabilities at the point of care, record and share heart sounds and ECGs, and remotely monitor patients for cardiac anomalies.
View Eko Analysis Software →Choose ElucidVivo A.3 if…
Choose ElucidVivo A.3 if you require advanced, quantitative analysis of arterial plaque composition and stability from CT angiography to optimize treatment decisions for atherosclerosis patients. This system is best suited for cardiologists, radiologists, and vascular surgeons who need detailed visualization of plaque characteristics, including lipid-rich necrotic core, and objective data to stratify patient risk and guide interventional strategies.
View ElucidVivo A.3 →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Eko Analysis Software | ElucidVivo A.3 |
|---|---|---|
| Deployment | Unknown | Cloud and on-premise secure deployment. |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Eko Analysis SoftwareEko Analysis Software (Tool A) integrates with digital stethoscopes and a mobile app, offering a freemium model that suggests a user-friendly, point-of-care experience. ElucidVivo A.3 (Tool B), while powerful, is a specialized medical image analysis system likely requiring integration into complex imaging workflows, which can be less immediately intuitive for general use.
Clinical Value
ElucidVivo A.3Both tools are FDA-cleared and offer significant clinical value. However, ElucidVivo A.3 (Tool B) provides a more advanced and specialized quantitative analysis of arterial plaque composition from CT angiography, validated against histology, and derives fractional flow reserve (FFRct), offering deeper diagnostic and prognostic insights for atherosclerosis patient stratification. Eko Analysis Software (Tool A) focuses on earlier detection of murmurs and AFib via auscultation.
Pricing & Value
Eko Analysis SoftwareEko Analysis Software (Tool A) offers a transparent freemium model, allowing users to access basic features for free before subscribing for full AI capabilities. ElucidVivo A.3 (Tool B) only states 'contact for pricing,' which lacks transparency and makes it difficult to assess its value proposition without direct inquiry.
Enterprise Readiness
Eko Analysis SoftwareEko Analysis Software (Tool A) explicitly states HIPAA compliance and the availability of a Business Associate Agreement (BAA), along with cloud-based deployment and secure storage. ElucidVivo A.3 (Tool B) implies HIPAA compliance and BAA but does not explicitly state them, and its deployment details are less specific, making Tool A more clearly enterprise-ready.
Innovation
ElucidVivo A.3While Eko Analysis Software (Tool A) innovates by bringing AI to point-of-care auscultation, ElucidVivo A.3 (Tool B) demonstrates a more profound innovation by applying AI to provide histologically validated, quantitative analysis of arterial plaque composition and FFRct derivation from CT angiography. This offers novel, detailed insights beyond standard imaging interpretation.
Support & Docs
Eko Analysis SoftwareEko Analysis Software (Tool A) offers a comprehensive Help Center with user manuals, quick start guides, FAQs, how-to videos, and direct support channels (email, phone, chat), including an SLA for enterprise customers. In contrast, the available information for ElucidVivo A.3 (Tool B) does not explicitly detail dedicated user support resources or documentation.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Eko Analysis Software | ElucidVivo A.3 |
|---|---|---|
| Tool Name | Eko Analysis Software | ElucidVivo A.3 |
| Company | Eko Devices | Elucid Bioimaging |
| Primary AI Focus | Assists clinicians in the early detection of cardiovascular diseases like heart murmurs and atrial fibrillation. | Provides quantitative analysis of arterial plaque composition and stability from CT angiography. It assists physicians in atherosclerosis patient stratification and optimizes treatment decisions. |
| Key Detection/Analysis Capabilities | FDA-cleared AI for heart murmur detection; FDA-cleared AI for atrial fibrillation (AFib) detection; Detection of normal sinus rhythm; Calculation of cardiac time intervals (heart rate, QRS duration); Recording, playback, and annotation of heart sounds and ECGs; Visualization of phonocardiograms (PCG) and ECG tracings. | AI-powered quantitative analysis of arterial plaque; Objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images; Visualizes lesion-level plaque composition; Provides 3D visualization of highlighted vessels; Derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity. |
| Input Data Type | Heart sounds and ECGs (from digital stethoscopes and mobile app) | CT angiography images |
Videos
Demos, reviews, and walkthroughs featuring Eko Analysis Software and ElucidVivo A.3.